• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一名患有肺动脉高压的婴儿从静脉注射曲前列尼尔过渡到口服司来帕格治疗。

Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension.

作者信息

Koo Rachel, Lo Jennifer, Bock Matthew J

机构信息

Department of Pediatrics,Loma Linda University Children's Health,Loma Linda, CA,USA.

Division of Pediatric Cardiology,Loma Linda University Children's Health,Loma Linda, CA,USA.

出版信息

Cardiol Young. 2019 Jun;29(6):849-851. doi: 10.1017/S1047951119001082.

DOI:10.1017/S1047951119001082
PMID:31379316
Abstract

Selexipag is an enteral, selective prostacyclin IP receptor agonist approved for pulmonary hypertension in adults. There are few reports of its use in children and none in infants. We report the first transition of an infant (11.5 months, 8.6 kg) from intravenous treprostinil (40 ng/kg/minute) to enteral selexipag (400 mcg twice daily) with a good response and no adverse effects.

摘要

司来帕格是一种经肠道给药的选择性前列环素 IP 受体激动剂，已被批准用于治疗成人肺动脉高压。关于其在儿童中的使用报道很少，在婴儿中则尚无相关报道。我们报告了首例婴儿（11.5 个月，8.6 千克）从静脉注射曲前列尼尔（40 纳克/千克/分钟）转换为口服司来帕格（每日两次，每次 400 微克）的病例，该婴儿反应良好且未出现不良反应。

相似文献

1
Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension.一名患有肺动脉高压的婴儿从静脉注射曲前列尼尔过渡到口服司来帕格治疗。
Cardiol Young. 2019 Jun;29(6):849-851. doi: 10.1017/S1047951119001082.
2
Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.从吸入性曲前列尼尔转换为口服塞来昔帕治疗肺动脉高压的安全性和耐受性：TRANSIT-1 研究结果。
J Heart Lung Transplant. 2019 Jan;38(1):43-50. doi: 10.1016/j.healun.2018.09.003. Epub 2018 Sep 12.
3
Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension.一名混合病因肺动脉高压患者从口服司来帕格快速转换为肠外使用曲前列尼尔的情况
Am J Health Syst Pharm. 2020 Jul 23;77(15):1208-1212. doi: 10.1093/ajhp/zxaa158.
4
Different efficacy of inhaled and oral medications in pulmonary hypertension.吸入药物与口服药物治疗肺动脉高压的疗效差异
Heart Lung. 2017 Jul-Aug;46(4):334-337. doi: 10.1016/j.hrtlng.2017.04.010. Epub 2017 May 17.
5
Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension.从肠外前列腺素到塞来昔帕用于肺动脉高压的转换经验。
J Cardiovasc Pharmacol. 2020 Apr;75(4):299-304. doi: 10.1097/FJC.0000000000000800.
6
Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE.SPHERE 真实世界研究中 500 例肺动脉高压患者使用塞乐西帕治疗的患者和疾病特征。
J Heart Lung Transplant. 2021 Apr;40(4):279-288. doi: 10.1016/j.healun.2021.01.006. Epub 2021 Jan 15.
7
Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy.西地那非治疗儿童肺动脉高压：药物安全性和疗效的首次多中心经验。
J Heart Lung Transplant. 2020 Jul;39(7):695-706. doi: 10.1016/j.healun.2020.03.029. Epub 2020 Apr 7.
8
Transition of Intravenous Treprostinil to Oral Therapy in a Patient with Functional Class IV Chronic Thromboembolic Pulmonary Hypertension.静脉注射曲前列尼尔向口服治疗转换：一例心功能 IV 级慢性血栓栓塞性肺动脉高压患者。
Pharmacotherapy. 2017 Aug;37(8):e76-e81. doi: 10.1002/phar.1951. Epub 2017 Jun 30.
9
Transition From Inhaled Treprostinil to Selexipag in Pulmonary Arterial Hypertension.肺动脉高压患者从吸入性曲前列尼尔转换为司来帕格的情况
Am J Ther. 2017 Sep/Oct;24(5):e620-e621. doi: 10.1097/MJT.0000000000000496.
10
Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study.在肺动脉高压患者中从口服转为静脉注射塞乐昔帕：一项开放标签、III 期研究的安全性、耐受性和药代动力学结果。
Respir Res. 2021 Feb 3;22(1):34. doi: 10.1186/s12931-020-01594-8.

引用本文的文献

1
Current and emerging pharmacotherapies for the treatment of pulmonary arterial hypertension in infants.当前和新兴的肺动脉高压治疗药物治疗婴儿的肺动脉高压。
Expert Opin Pharmacother. 2023 Sep-Dec;24(17):1875-1886. doi: 10.1080/14656566.2023.2257598. Epub 2023 Sep 14.
2
Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration.病例报告：司来帕格用于小儿肺动脉高压：起始、转换及滴定
Front Pediatr. 2023 Mar 8;11:1050508. doi: 10.3389/fped.2023.1050508. eCollection 2023.
3
A Canadian, retrospective, multicenter experience with selexipag for a heterogeneous group of pediatric pulmonary hypertension patients.
一项针对不同类型小儿肺动脉高压患者使用司来帕格的加拿大回顾性多中心研究。
Front Pediatr. 2023 Feb 28;11:1055158. doi: 10.3389/fped.2023.1055158. eCollection 2023.
4
Safety and Tolerability of a Rapid Transition From Intravenous Treprostinil to Oral Selexipag in Three Adolescent Patients With Pulmonary Arterial Hypertension.三名青少年肺动脉高压患者从静脉注射曲前列尼尔快速转换为口服司来帕格的安全性和耐受性
J Pediatr Pharmacol Ther. 2021;26(5):512-516. doi: 10.5863/1551-6776-26.5.512. Epub 2021 Jun 28.
5
Early diagnosis and targeted approaches to pulmonary vascular disease in bronchopulmonary dysplasia.支气管肺发育不良中肺血管疾病的早期诊断和靶向治疗方法。
Pediatr Res. 2022 Mar;91(4):804-815. doi: 10.1038/s41390-021-01413-w. Epub 2021 Mar 5.